Evidence map›Paper›PMID 41501498›Full record

ArticleNature medicine2026

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Stefanie Göllner, Thomas Oellerich, Shuchi Agrawal-Singh, Tino Schenk, Hans-Ulrich Klein, Christian Rohde, Caroline Pabst, Tim Sauer, Mads Lerdrup, Sigal Tavor and 18 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Stefanie GöllnerDepartment of Medicine IV, Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Germany. stefanie.goellner@med.uni-heidelberg.de.
Thomas Oellerich *Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.
Shuchi Agrawal-Singh *Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark.
Tino SchenkInstitute of Cancer Research (ICR), Molecular Pathology, London, UK.
Hans-Ulrich KleinInstitute of Medical Informatics, University Hospital of Münster, Münster, Germany.
Christian RohdeDepartment of Medicine IV, Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Germany.
Caroline PabstDepartment of Medicine IV, Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Germany.
Tim SauerDepartment of Medicine IV, Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Germany.
Mads LerdrupBiotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark.
Sigal TavorGoldyne Savad Institute of Gene Therapy, Jerusalem, Israel.
Friedrich StölzelDepartment of Medicine, Molecular Hematology, University Hospital Carl Gustav Carus, Dresden, Germany.
Sylvia HeroldDepartment of Medicine, Molecular Hematology, University Hospital Carl Gustav Carus, Dresden, Germany.
Gerhard EhningerDepartment of Medicine, Molecular Hematology, University Hospital Carl Gustav Carus, Dresden, Germany.
Gabriele KöhlerGerhard Domagk Institute of Pathology, University of Münster, Münster, Germany.
Kuan-Ting PanBioanalytical Mass Spectrometry Group, Max Plank Institute for Biophysical Chemistry, Goettingen, Germany.
Henning UrlaubBioanalytical Mass Spectrometry Group, Max Plank Institute for Biophysical Chemistry, Goettingen, Germany.
Hubert ServeDepartment of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.
Martin DugasInstitute of Medical Informatics, University Hospital of Münster, Münster, Germany.
Karsten SpiekermannGerman Cancer Consortium (DKTK), Heidelberg, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Binje VickGerman Cancer Consortium (DKTK), Heidelberg, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Irmela JeremiasGerman Cancer Consortium (DKTK), Heidelberg, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wolfgang E BerdelDepartment of Medicine A, Hematology and Oncology, University Hospital of Münster, Münster, Germany.
Klaus HansenBiotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark.
Arthur ZelentSylvester Comprehensive Cancer Center (UMHC), University of Miami Hospital and Clinics, Miami, Florida, USA.
Claudia WickenhauserDepartment of Pathology, University Hospital of Halle (Saale), Halle (Saale), Germany.
Lutz P MüllerDepartment of Medicine IV, Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Germany.
Christian ThiedeDepartment of Medicine, Molecular Hematology, University Hospital Carl Gustav Carus, Dresden, Germany.
Carsten Müller-TidowDepartment of Medicine IV, Hematology and Oncology, University Hospital of Halle (Saale), Halle (Saale), Germany. carsten.mueller-tidow@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41501498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.